Ajinomoto Bio-Pharma Services Garners Six 'CDMO Leadership Awards,' Further Establishing Its Industry Excellence

March 12, 2024 11:00 PM AEDT | By Cision

Ajinomoto Bio-Pharma Services Garners Six 'CDMO Leadership Awards,' Further Establishing Its Industry Excellence — Image source: Kalkine Media

Recent News

Civmec Secures $285M in Major Projects, Strengthening Its Role in ASX2...

Sigma Healthcare Merger Boosts Earnings Amid ASX200 Spotlight

CSL Faces US Vaccination Headwinds, Eyes Growth in Europe Amid ASX200...

Strategic Momentum: International Graphite’s Projects Advance Amid Str...

SAN DIEGO and TOKYO and WETTEREN, Belgium, March 12, 2024 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, received CDMO Leadership Awards in all six categories - Capabilities, Compatibility, Expertise, Quality, Reliability, and Service for both the Overall and Big Pharma respondent groups. Of the awards listed, Aji Bio-Pharma was given additional recognition as a CDMO Leadership Award Champion in the Service category for the Small Pharma respondent group by scoring as a top performer in comparison to the weighted average of other CDMOs evaluated.

The CDMO Leadership Awards are presented by Outsourced Pharma, Life Science Leader, and Industry Standard Research. Respondents evaluated 98 contract manufacturers across 23 performance metrics in ISR's annual Contract Manufacturing Quality Benchmarking survey. Respondents only evaluate companies with which they have worked on an outsourced project within the past 18 months. This level of qualification ensures that survey responses are based on actual involvement with contract manufacturers and clear experiential data to recognize top outsourcing partners.

"We are honored to be recognized in every category by our partners. With each investment in technology, quality, and facilities, we elevate our capabilities, ensuring we meet and exceed our client's needs. We pride ourselves in not just fulfilling client expectations, but also serving countless patients for years to come," said Yasuyuki Otake, Corporate Executive, General Manager, Bio-Pharma Services Department.

About Ajinomoto Bio-Pharma Services

Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with sites in Belgium, United States, Japan, and India, providing comprehensive development, cGMP manufacturing, and aseptic fill finish services for small and large molecule APIs and intermediates. Ajinomoto Bio-Pharma Services offers a broad range of innovative platforms and capabilities for pre-clinical and pilot programs to commercial quantities, including Corynex® protein expression technology, oligonucleotide synthesis, antibody drug conjugations (ADC), high potency APIs (HPAPI), biocatalysis, continuous flow manufacturing, and more. Ajinomoto Bio-Pharma Services is dedicated to providing a high level of quality and service to meet its client's needs. Learn more: www.AjiBio-Pharma.com

Logo - https://mma.prnasia.com/media2/751177/Aji_BioPharma_Logo.jpg?p=medium600

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.